A new study from the American Association for the Study of Liver Diseases reports that over 2 million people in the United States had current HCV infection during 2013‐2016. The findings of the study suggest that the previous 2013-2016 US HCV prevalence estimate derived from NHANES alone underestimates the actual number of HCV Read more…
FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) announced today plans to launch authorized generic versions of Epclusa®(sofosbuvir 400mg/velpatasvir 100mg) and Harvoni®(ledipasvir 90mg/sofosbuvir 400mg), Gilead’s leading treatments for chronic hepatitis C virus (HCV), in the United States, through a newly created subsidiary, Asegua Therapeutics LLC. The authorized generics will launch Read more…
Today is International Overdose Awareness Day. As we take the time to remember friends and community members we’ve lost, we can also show solidarity by showing up for those affected by and fighting the opioid epidemic. Saturday 9/1: Hike Against Heroin on Forbidden Drive : https://www.eventbrite.com/e/international-overdose-awareness-day-hike-against-heroin-tickets-48397960603 Check out https://www.overdoseday.com/ for information about Read more…
Liver cancer death rates among adults continue to climb nationwide, according to new data released by the CDC. Past studies have linked it to high rates of hepatitis C infection among baby boomers and the growing prevalence of obesity and type 2 diabetes. The new numbers reveal other demographic trends Read more…
Commissioner Farley named improving Hepatitis C prevention and treatment as one of the two strategic goals of the Division of Disease Control in his testimony on the Department of Public Health’s Fiscal Year 2019 Operating Budget. Specifically, the Division of Disease Control will aim to “increase the proportion of reported Read more…
This May, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) updated their HCV screening and treatment recommendations to focus on eradicating HCV among key populations; including pregnant women who previously were not regularly screened, people who inject drugs, men who Read more…
The O’Neill Institute of Georgetown Law School has released a report highlighting the stories of women and men who have faced Hepatitis C. A publication by the Hepatitis Policy Project, “Full of Life: The Stories of People Affected by Hepatitis C” reveals the human impacts of treatment and policy, and Read more…
Access Minutes Here The Committee reviewed the Hepatitis C Agents class and unaminously approved adding Mavyret to the PDL at preferred status, moving Pegasys, Pegintron, Sovaldi, Technivie, Viekira Pak and Viekira XR to non-preferred status, and adding Vosevi to the PDL at non-preferred status. The Committee recognized the changing landscape Read more…
The Franklin Institute has done a highlight article of our Community Co-Chair Stacey! ” PHILADELPHIA WOMEN IN SCIENCE May is Hepatitis Awareness Month, so it’s fitting that our Women in Science series features infectious disease specialist Dr. Stacey Trooskin, who is helping lead Philadelphia’s charge to eliminate hepatitis C from Read more…
Governor Andrew M. Cuomo today announced he is advancing a statewide expansion of the HIV/AIDS Services Administration rental assistance program for New Yorkers living with HIV/AIDS. Additionally, the Governor announced the nation’s first state-level Hepatitis C comprehensive elimination strategy to end the Hepatitis C and HIV epidemics in New York Read more…